IDMC recommends to continue patient enrolment in Ph 1 ZIMA-101 trial in solid tumor patients August 25, 2026
First Patient Dosed in MODeFIRe-1 Ph 2 Study of MRT-2359 + Apalutamide in Patients with AR Mutation-Positive Metastatic CRPC August 25, 2026
SUPRAME topline data disclosure for the final PFS analysis expected in H1 2027, followed by BLA submission in 2027 August 25, 2026
Enrollment opens in Ph 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101 August 25, 2026
Patient enrollment completed in Ph 3 TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer August 20, 2026
IDMC recommends discontinuing the eVOLVE-Lung02 Ph 3 trial of volrustomig + chemo in 1L metastatic NSCLC with PD-L1 <50% August 20, 2026
ACR-2316 advances into dose expansion portion of Ph 1/2 study in SCLC, squamous NSCLC, lung adenocarcinoma (adNSCLC), endometrial, cervical, and GEJ cancers August 11, 2026
First Patient Dosed in Registrational Study of IBI363/TAK-928 in Combination with Bevacizumab in Late-Line Advanced CRC in China August 11, 2026
IDE892 Initiates Part 2 Monotherapy Expansion in Ph 1/2 Study in MTAP-Deleted Pancreatic & Lung Cancers August 5, 2026
Final subject received last dose of Ampligen (rintatolimod) in Ph 2 DURIPANC trial of Ampligen + Imfinzi for the treatment of metastatic pancreatic cancer August 5, 2026
Strong Enrollment Momentum Reported in Ph 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer August 5, 2026
First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell NHL July 28, 2026
